Oyster Point Pharma Inc

Oyster Point Pharma — Technical Presentation (January 2020)

21 slides from Oyster Point Pharma's technical presentation, Jan 13, 2020

  1. Slide 1: Phase II Topline Data Release: MYSTIC Study in Dry Eye Disease

    NASDAQ: OYST January 13, 2020 PHASE II TOPLINE DATA RELEASE MYSTIC The Study In Dry Eye Disease Exhibit 99.2

  2. Slide 2: Disclaimers and Forward Looking Statements

    Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “we” or “our”) reg

  3. Slide 3: Redefining Dry Eye Treatment with a Nasal Spray

    Redefining Dry Eye Treatment with a Nasal Spray

  4. Slide 4: There is No Substitute for Natural Tear Film

    There is No Substitute for Natural Tear Film Natural tears contain a complex mixture of lipids, proteins, mucins, and electrolytes Over 1,500 proteins 5+ lipid classes 20+ mucins Growth factors, such as nerve growth factor (NGF) and epidermal growth factor (EGF), found in natural human tears are cri

  5. Slide 5: Tear Film is Produced by the Lacrimal Functional Unit

    Tear Film is Produced by the Lacrimal Functional Unit LACRIMAL GLANDS Produce the aqueous which contains proteins, enzymes, antibodies and growth factors that are cytoprotective, anti-inflammatory, and anti-microbial. aqueous mucins lipid layer MEIBOMIAN GLANDS Produce the lipid layer which reduces

  6. Slide 6: Loss of Tear Film Leads to Progression of Dry Eye Disease

    Loss of Tear Film Leads to Progression of Dry Eye Disease Epithelial Cells Mucin Aqueous Lipid Healthy Ocular Surface Tear Film Homeostasis Loss of Tear Film Homeostasis Fundamental Characteristic of DED Cycle of Dry Eye Disease Leads to Inflammation and Cell Damage Increased Evaporation Decreased T

  7. Slide 7: OC-01 Breaks this Cycle to Re-Establish Natural Tear Film Production

    OC-01 Breaks this Cycle to Re-Establish Natural Tear Film Production through its Novel MOA Epithelial Cells Mucin Aqueous Lipid Healthy Ocular Surface Tear Film Homeostasis Loss of Tear Film Homeostasis Fundamental Characteristic of DED Cycle of Dry Eye Disease Leads to Inflammation and Cell Damage

  8. Slide 8: Nasal Delivery is Critical to the Novel MOA

    Nasal Delivery is Critical to the Novel MOA The trigeminal nerve provides the pathway for parasympathetic stimulation of the Lacrimal Functional Unit (LFU) to promote complete natural tear film The trigeminal nerve is accessible within the nasal cavity and can be activated by stimulating nicotinic a

  9. Slide 9: OC-01 is a Selective Nicotinic Agonist

    OC-01 is a Selective Nicotinic Agonist Preservative-free nasal spray containing the selective nicotinic acetylcholine receptor agonist, varenicline. Binds to receptors located on the trigeminal nerve readily accessible within anterior portion of the nasal cavity to open ion channels and depolarize t

  10. Slide 10: OC-01 Nasal Spray Clinical Development Program

    OC-01 Nasal Spray Clinical Development Program Dry Eye Disease PHASE 1 PHASE 2b PHASE 2 PHASE 3 PK Study 28-Day Safety & Efficacy Long-term 84 Day Safety & Efficacy 28-Day Efficacy & Safety Complete Complete Complete Top-Line Expected Mid-2020 Planning OC-01 label expansion for contact lens intolera

  11. Slide 11: Phase 2 Study: Evaluating Long-term Safety and Efficacy

    Phase 2 Study: Evaluating Long-term Safety and Efficacy Study Rationale: Evaluate long-term (Day 84) safety and efficacy of nicotinic agonist stimulation of the trigeminal parasympathetic pathway Met the Primary Endpoint of Mean Change in Schirmer’s Score vs. Control at Day 84 Statistically signific

  12. Slide 12: OC-01 Phase 2 Study Design

    Single center, randomized, controlled, single-masked clinical trial to evaluate the chronic efficacy of OC-01 nasal spray on signs of dry eye disease OC-01 Phase 2 Study Design Diagnosed Dry Eye Disease >22 yrs old Schirmer’s Score ≤10 mm Placebo (Vehicle Control) 0.6 mg/ml OC-01 Nasal Spray 1.2 mg/

  13. Slide 13: MYSTIC Subject Demographics

    MYSTIC Subject Demographics Mean Age at Randomization (years) Sex Male n (%) Female n (%) Race White n (%) Black or African American n (%) Asian n (%) Other n (%) Ethnicity Not Hispanic or Latino n (%) Hispanic or Latino n (%) Age Range (min, max) Mean Baseline Schirmer’s Test (with anesthesia, mm)

  14. Slide 14: Study Eye Primary Endpoint: Significant Improvement in Schirmer's Score at Day 84

    Study Eye- Primary Endpoint Statistically Significant Improvement In Schirmer’s Score at Day 84 Mean Change in Schirmer’s Score* (mm) Study Eye Mean Change from Baseline in Schirmer’s Score (mm) Intent To Treat-Last Observation Carried Forward * ANCOVA, Least Squares mean Intent To Treat- Observed *

  15. Slide 15: Fellow Eye Exploratory: Significant Improvement in Schirmer's Score at Day 84

    Fellow Eye- Exploratory Statistically Significant Improvement In Schirmer’s Score at Day 84 Mean Change in Schirmer’s Score* (mm) Fellow Eye Mean Change from Baseline in Schirmer’s Score (mm) Intent To Treat-Last Observation Carried Forward * ANCOVA, Least Squares mean Intent To Treat- Observed * AN

  16. Slide 16: Study Eye Showed Early and Sustained Improvement in Schirmer's Score

    Study Eye Showed Early and Sustained Improvement In Schirmer’s Score to Day 84 Mean Change in Schirmer’s Score* (mm) Highlights: Early Improvement in mean change in Schirmer’s score for both groups in the study eye Consistent tear film production with twice daily dosing at all visits to Day 84 Study

  17. Slide 17: Magnitude of Tear Production Consistent with Prior Studies at Day 28

    Magnitude of Tear Production Consistent with Prior Studies of OC-01 at Day 28 MYSTIC Intent To Treat- Observed * ANCOVA, Least Squares mean Mean Change in Schirmer’s Score* (mm) Mean Change in Schirmer’s Score* (mm) n=46 n=40 n=34 n=31

  18. Slide 18: OC-01 Safety and Tolerability Profile

    OC-01 Safety and Tolerability Profile Adverse Event (Preferred Term) OC-01 (0.6 mg/mL) (n=41) n (%) OC-01 (1.2 mg/mL) (n=41) n (%) Placebo (vehicle control) (n=41) n (%) Visual Acuity Reduced 4 (9.8) 1 (2.4) 0 Sneeze after any instillation 2 (4.9) 3 (7.3) 2 (4.9) Headache 2 (4.9) 2 (4.9) 0 Throat ir

  19. Slide 19: Next: Pivotal Phase Data; Topline Data On Track for Mid-2020

    Next: Pivotal Phase 3 Data; Topline Data On Track for Mid-2020 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease Diagnosed Dry Eye Disease Schirmer’s Score ≤10 mm OSDI ≥23 Placebo (Vehic

  20. Slide 20: OC-01 Nasal Spray Expected Timeline to Approval

    OC-01 Nasal Spray Expected Timeline to Approval Enrollment Complete- Q3 2018 Enrollment Complete- 1H 2020 Topline Data (Day 28)- MID 2020 NDA Submission - 2H 2020 NDA Approval - 2H 2021 New Drug Application Enrollment Complete - Q3 2019 Topline Data - Q4 2019 MYSTIC Enrollment Complete - Q3 2019 Top

  21. Slide 21: Oyster Point Pharma

    OYSTER ZS. OPO a NASDAQ: OYST

Oyster Point Pharma — Technical Presentation (January 2020) on 6ix